<DOC>
	<DOCNO>NCT00388674</DOCNO>
	<brief_summary>The purpose study prospectively assess long-term outcome ( benefit risk ) associate entecavir ( ETV ) therapy compare antiviral approve treatment chronic HBV infection . For China substudy , patient randomize entecavir safety efficacy assessment perform first year study .</brief_summary>
	<brief_title>Study Entecavir Patients With Chronic Hepatitis B Virus ( HBV ) Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Chronic HBV infection HBV nucleoside/tidenaive experience Patients , opinion investigator , appropriate initiate modify HBV therapy appropriate treatment regimen comprise nucleoside/tide monotherapy either ETV another standard care HBV nucleoside/tide analogue Age 16 old minimum age require give country Women pregnant breastfeeding Patients , opinion investigator , expect liver transplantfree survival less one year Patients , opinion investigator , virologically control current treatment regimen clinically respond treatment , unless regimen need modified medication intolerance Coinfection HIV History malignant neoplasm ( ) , include hepatocellular carcinoma ( HCC ) carcinoma situ ( CIS ) , exclude nonmelanoma skin cancer Patients chronic renal insufficiency , define creatinine clearance &lt; 50 ml/min either follow mean dose reduce ETV : i. approve countryspecific ETV label include extended interval ETV dose modification method and/or ii . approve country specific label ETV oral solution AND access oral solution History dysplastic liver nodule Known history allergy nucleoside/tide analogue Prior current treatment entecavir An investigator propose study regimen include interferonalfa An investigator propose study regimen combination ( two ) HBV nucleoside/tide analogue</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Chronic Hepatitis B Virus</keyword>
</DOC>